360 Capital Group (TGP) News

Would be nice. See what next week brings.

Not even Elon Musk could afford

to buy on every dip with this company. It is one nonstop long dip.

This might be huge:



AIM ImmunoTech Granted U.S. Patent for Ampligen® for the Treatment of Endometriosis

Source: GlobeNewswire Inc.

AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the United States Pat

Good for Nvidia

Data center finance leases
Buried within the footnote of its quarterly and annual reports, Microsoft lists the number of finance leases, mostly for data centers, that have yet to commence. The details include the amount of money it has contracted out for leases

I'm hoping that you are correct.


- Has the company even applied for it?
- Why is the company so dull and not enthusiastically touting their accomplishments?
- Their website sucks and is outdated by a few years.
- We do not hear a word from them on anyth

lj: Florida weather
Thanks for the weather forecast video. A neighbor just cancelled her planned trip to Florida next week to visit her elderly mother.

lj: re: interest rates
I think we are in a mild recession. When you don't see many cars at fast-food drive throughs, something is going on.
Egg prices are ridiculous. Eggs are in many food products. IMO, a big part of food inflation.

In Mexico, ‘It’s Time for Women’

"Who is Claudia Sheinbaum? Here’s what to know about Mexico’s next president"

Claudia Sheinbaum took office on Tuesday as the country’s first female president.

By Catherine Osborn, the writer of Foreign Policy’s weekly Lat

lj: Agree about the tax-loss selling this year. Not much out there to push up the market.
The election is a factor that should keep the market down for a month.

https://www.gq.com/story/californias-vanishing-hippie-utopias

😂😂😂😂🤡

If merck want nwbo they still have time to make a purchase. They (MRK)may not think the market for gbm (dcvax plus keytruda) is large enough for them in terms of revenue especially until approved by fda. Should we get approval by MHRA merck may take an interest as then better chance for fda/usa appr

Cool.
Does Shaun the Sheep and Epaz know this ?
Do they have that information ?

Whats a reasonable Market Cap for 4 million in revenue. No debt. 9-10 million next year. Patents and no reverse split. &dvm traded up too 21,000 million with less revenue or similiar. I feel anywhere between 9-24 million is a reasonable area and range for Sinc.

There you go spinning nonsense again, Proto. Stephano Slack is a rinky-dink regional firm, wholly inappropriate for an alleged soon to be ubiquitous Nasdaq tech company. This proves again that LWLG is still playing in the minors, hoping one day to make it to the big leagues.

This is

The cult page wants an update from the receiver. If he did give one, it would be real simple. “Boys, you’re screwed”. Lol. Some clowns from the cult actually think the receiver is going to move the company forward. lol. Little do they know, he is unwinding it.

Re: still incoming from lawsuits?

Also, it says there will be a small group of administrator staff to remain and manage other litigations.

I EXPLAINED IT MANY TIMES

Check the cash flow. 210M is the only asset left to distribute. Ecaps money not included.

Merck could be sitting alone wondering what could have been.
It's exactly what I've been thinking... While we are all focused on Merck, it may well be someone we haven't even considered.



.

ILUS leadership can’t merge into traffic much less merge companies. Heck can’t even change their name for how many years now. Got to hand it to them with dogged determination to the grift.

RE: still incoming from lawsuits?

Nothing is coming other than ecaps money. Read the quarterly report. It says money from ecaps not included in the recovery.

Shadyland scam just like BRYYF. His comical chart posts with that fictitious upward spike that never comes,

Very nice. How did i miss it earlier, and how in hell did i get back
there just now. LOL It's a good view Jacy, of the two of you.

"...Cognision, providers of advanced neurobiomarker technology, announces its partnership with Anavex Life Sciences Corp. (Nasdaq: AVXL), in a phase 2 clinical trial of ANAVEX®3-71 in subjects with schizophrenia.

ANAVEX®3-71 is a therapeutic agent with a dual mecha

Steve Schmidt is always good. "Decency is making a comeback in America" And that's a good thing.